Clinical Trial

A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Name: A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease — clinical trial record (NCT04232553)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: VIVID-2

Active, Not Recruiting Phase 3

View on ClinicalTrials.gov →

Summary

The reason for this study is to determine the long-term efficacy and safety of the study drug mirikizumab in participants with Crohn's disease.

Protocol Amendment History 1 change

minor Completion pushed: 2027-04 -> 2028-03 2026-08-12

Trial Details

NCT Number	NCT04232553
Lead Sponsor	Eli Lilly and Company
Conditions	Crohn's Disease
Enrollment	996 participants
Start Date	2020-06-22
Primary Completion	2024-11-28 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2026-08-11